Form 4: Oramed Director Aghion Increases Stake with RSU Awards

Oramed Pharmaceuticals Director Daniel Aghion acquired 36,250 Restricted Stock Units, increasing his direct beneficial ownership to 113,441 shares.

Summary

• Daniel Aghion, a Director of Oramed Pharmaceuticals Inc. (ORMP), reported an acquisition of common stock.
• The transaction occurred on December 31, 2025.
• Aghion acquired a total of 36,250 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• One tranche of 30,000 RSUs will vest ratably in three annual installments beginning January 1, 2027.
• Another tranche of 6,250 RSUs will vest in quarterly installments over a one-year period starting April 1, 2026.
• Following these transactions, Aghion directly beneficially owns 113,441 shares of Common Stock.

Sentiment

Score: 7

Explanation: The acquisition of Restricted Stock Units by a director is generally viewed positively as it increases insider alignment with shareholder interests, although it is a form of compensation rather than an open market purchase.

Positives

• Increased direct beneficial ownership by a company director, potentially signaling confidence in the company's future.
• The acquisition of 36,250 Restricted Stock Units (RSUs) aligns the director's interests with long-term shareholder value.

Risks

• The value of the acquired RSUs is subject to the future performance of Oramed Pharmaceuticals' common stock.
• Vesting schedules for the RSUs extend into 2026 and 2027, meaning the director's full ownership is contingent on continued employment or board service and company performance.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's operational or financial performance, focusing solely on insider ownership changes.

Industry Context

This Form 4 filing reflects a routine insider equity award, common in the pharmaceutical industry as a form of executive and director compensation to align interests with long-term company performance. It does not provide specific insights into broader industry trends or competitive positioning.

Related Party Transactions

• The acquisition of Restricted Stock Units by Director Daniel Aghion represents equity compensation, which is a common form of transaction between a company and its directors/executives.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to higher beneficial ownership.

Next Steps

• The 30,000 RSUs will vest ratably in three annual tranches beginning January 1, 2027.
• The 6,250 RSUs will vest in quarterly installments over a one-year period starting April 1, 2026.

Key Dates

Keywords

Oramed Pharmaceuticals, ORMP, Daniel Aghion, Form 4, Insider Trading, Restricted Stock Units, RSUs, Director Ownership, Beneficial Ownership, Equity Compensation